Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Onyx Pharmaceuticals, Inc.

http://www.onyx-pharm.com

Latest From Onyx Pharmaceuticals, Inc.

Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Gene Therapy Approvals

Happify Health Collaborates With Biogen To Support People Living With Multiple Sclerosis

Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.

Digital Health Deals

Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market

Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.

Financing Business Strategies

Eiger Expects To Join Gilead In Future Multi-Billion Dollar Hepatitis D Market

The little-known company could be set for a transformational year, with a Phase III readout in hepatitis D and a filing for a promising COVID-19 candidate.

Companies Commercial
See All

Company Information

  • Other Names / Subsidiaries
    • Proteolix, Inc.
UsernamePublicRestriction

Register